Bain Capital Amends Coherent Corp. Stake Filing

TL;DR

Bain Capital updated its Coherent Corp. filing, showing a change in their beneficial ownership.

AI Summary

Bain Capital Investors, LLC, through its affiliate BCPE Watson (DE) BML, LP, has filed an amendment (Amendment No. 1) to its Schedule 13D on March 7, 2024, regarding its holdings in Coherent Corp. The filing indicates a change in the beneficial ownership of Coherent Corp. common stock, with BCPE Watson (DE) BML, LP now holding a significant stake.

Why It Matters

This amendment signals a potential shift in control or influence for Coherent Corp., as a major investment firm has updated its stake. Investors will monitor future actions for potential strategic moves.

Risk Assessment

Risk Level: medium — Amendments to Schedule 13D filings often indicate significant changes in a major shareholder's position, which can lead to increased volatility and strategic shifts for the company.

Key Players & Entities

• Bain Capital Investors, LLC (company) — Filing entity
• BCPE Watson (DE) BML, LP (company) — Affiliate of Bain Capital Investors, LLC
• Coherent Corp. (company) — Subject company
• 200 Clarendon Street, Boston, MA 02116 (address) — Address of Bain Capital Investors, LLC
• 617-516-2000 (phone_number) — Phone number of Bain Capital Investors, LLC

FAQ

Key Financial Figures

• $1,320,000,000 — , increase the aggregate loan amount to $1,320,000,000, less certain fees and expenses (the BM

Filing Documents

• d807180dsc13da.htm (SC 13D/A) — 44KB
• 0001193125-24-062282.txt ( ) — 45KB

of the Initial Statement is hereby amended and supplemented to add the following

Item 3 of the Initial Statement is hereby amended and supplemented to add the following: On March 5, 2024, BML entered into an Increase Supplement and Amendment Agreement with the lenders party thereto, Morgan Stanley & Co. LLC, in its capacity as securities intermediary, calculation agent, collateral agent and collateral administrator under the BML Margin Loan Agreement and Morgan Stanley Senior Funding, Inc., in its capacity as administrative agent under the BML Margin Loan Agreement, which amended the BML Margin Loan Agreement to, among other things, increase the aggregate loan amount to $1,320,000,000, less certain fees and expenses (the BML Margin Loan Amendment). Proceeds from the BML Margin Loan Amendment were used to repay in full the aggregate loan amount outstanding under the ORML Margin Loan Agreement. Also on March 5, 2024 and upon the discharge of the ORML Margin Loan Agreement, the 65,000 shares of Series B-2 Preferred Stock held by ORML were transferred to BML and were pledged by BML as collateral for the ratable benefit of the lenders to secure BMLs obligations under the BML Margin Loan Agreement. Item5. Interest in Securities of the Issuer Item 5 of the Initial Statement is hereby amended and restated as follows: The information set forth in Items 2 and 3 and on the cover pages of this Schedule 13D is incorporated by reference in its entirety into this Item 5. (a) (c) The percentage of the Issuers outstanding shares of Common Stock held by the Reporting Persons is based on 151,813,356 shares of Common Stock outstanding as of February 2, 2024, as disclosed by the Issuer in its Quarterly Report on Form 10-Q for the quarter ended December 31, 2023. As of March 5, 2024, BML held 75,000 shares of Series B-1 Preferred Stock and 140,000 shares of Series B-2 Preferred Stock. Pursuant to the terms of the Statement with Respect to Shares, as of March 5, 2024, such shares were convertible into 10,207,302 and 17,904,349 shares of Common Stock, respe

SIGNATURES

SIGNATURES After reasonable inquiry and to the best of its knowledge and belief, the undersigned certifies that the information set forth in this statement is true, complete and correct. Dated: March 7, 2024 BCPE Watson (DE) BML, LP By: BCPE Watson (DE) BML GP, LLC, its general partner By: /s/ Joseph Robbins Name: Joseph Robbins Title: Authorized Signatory BCPE Watson (DE) ORML, LP By: BCPE Watson (DE) ORML GP, LLC, its general partner By: /s/ Joseph Robbins Name: Joseph Robbins Title: Authorized Signatory

View Full Filing

View this SC 13D/A filing on SEC EDGAR